The sponsors meeting & the first general meeting of shareholders was successfully held at the company headquarters on December 20, 2021.  With the approval of all sponsors, the company was reconstructed from ‘Guangzhou BeBetter Medicine Technology Co., Ltd.’to‘BeBetter Med Inc.’ 

The sponsors meeting was chaired by Dr. Changgeng Qian, the founder of BeBetter Med Inc. All sponsors of the company attended the meeting, and representatives of intermediaries that provided services to the company during the share reform period attended the meeting. At the meeting, voting was held successfully and all the proposals were passed by sponsors. The first session of board of directors, board of supervisors and other senior management members of BeBetter Med Inc. were selected through voting. 

Dr. Qian Changgeng expressed his warmest welcome and most sincere thanks to all the guests who attended the meeting. He said that it has been ten years since he returned to China and founded BeBetter Med Inc. in 2012. With the strong support from all new and old shareholders and through the unremitting efforts of all employees of the company, a top-tier new drug research and development team has been established, and a rich and highly competitive new drug pipeline has been built (including 11 independent innovation Class I new drug projects, and a total of 25 clinical trial approvals have been obtained). BeBetter Med Inc. has become an outstanding enterprise leading the independent research and development of innovative drugs in China. In 2022, the company will announce its initial public offering (STAR Offering) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE) and the NDA of the world's first-in-class new drug BEBT-908. At the same time, the innovative new drugs BEBT-209 and BEBT-109 will enter Phase III clinical trials and pivotal Phase II clinical trials respectively, in addition to multiple other new drugs entering clinical trial stage. BeBetter Med Inc. will continue to make unremitting efforts to achieve our vision of "Better Medicine, Better Health, Better Tomorrow!" 

At the meeting, Mr. Ju Hu, General Manager of Ruixiangyuan Fund, Mr. Jiajun Lai, Head of Yuexiu Industry Investment Department, Executive Director of Guokejiahe Dr. Jing Zhong delivered speeches on behalf of the sponsors. Vice President Mr. Yan Xiong and Independent Director of Hunan University School of Business Administration, Professor Guiliang Liu delivered speeches on behalf of the board of directors. Mr. Jie Cheng, member of CITIC Securities Global Investment Banking Committee and head of the healthcare industry group, delivered a speech on behalf of intermediaries. Everyone shared views on the status quo of innovative drug development in China, company development strategies, capital market status and other topics, which brought up many positive suggestions and feedbacks. 

The convening of this meeting is an important milestone in the company's development process, which marks the start of a new development era of BeBetter Med Inc. We will continue to adhere to our vision of "guided by clinical needs, focusing on the research and development of original innovative drugs, determined to innovate, and pursuing better". We will be committed to become a leading pharmaceutical enterprise with integrated functions of innovative R&D, manufacturing, service and business development, which also enables us to give back to the society and our shareholders!